The stock of MiMedx Group Inc (NASDAQ:MDXG) hit a new 52-week high and has $10.27 target or 3.00% above today’s $9.97 share price. The 9 months bullish chart indicates low risk for the $1.11 billion company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $10.27 price target is reached, the company will be worth $33.30 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 272,589 shares traded hands. MiMedx Group Inc (NASDAQ:MDXG) has risen 23.33% since April 22, 2016 and is uptrending. It has outperformed by 17.92% the S&P500.
Analysts await MiMedx Group Inc (NASDAQ:MDXG) to report earnings on February, 28. They expect $0.07 earnings per share, down 41.67% or $0.05 from last year’s $0.12 per share. MDXG’s profit will be $7.79M for 35.61 P/E if the $0.07 EPS becomes a reality. After $0.03 actual earnings per share reported by MiMedx Group Inc for the previous quarter, Wall Street now forecasts 133.33% EPS growth.
MiMedx Group Inc (NASDAQ:MDXG) Ratings Coverage
Out of 6 analysts covering MiMedx Group (NASDAQ:MDXG), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. MiMedx Group has been the topic of 8 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Needham maintained MiMedx Group Inc (NASDAQ:MDXG) rating on Wednesday, October 14. Needham has “Buy” rating and $13 price target. The firm has “Strong Buy” rating by Needham given on Monday, November 16. Needham downgraded it to “Buy” rating and $15 target price in Wednesday, July 29 report. The stock of MiMedx Group Inc (NASDAQ:MDXG) has “Buy” rating given on Tuesday, November 8 by Aegis Capital. The stock of MiMedx Group Inc (NASDAQ:MDXG) earned “Outperform” rating by Northland Capital on Friday, October 30. The company was maintained on Friday, December 18 by Canaccord Genuity. The rating was maintained by First Analysis with “Overweight” on Wednesday, January 20. On Tuesday, April 19 the stock rating was maintained by Lake Street with “Buy”.
According to Zacks Investment Research, “MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.”
Insitutional Activity: The institutional sentiment increased to 1.15 in 2016 Q2. Its up 0.12, from 1.03 in 2016Q1. The ratio improved, as 22 funds sold all MiMedx Group Inc shares owned while 49 reduced positions. 21 funds bought stakes while 52 increased positions. They now own 47.18 million shares or 4.50% more from 45.15 million shares in 2016Q1.
Westwood Mngmt Il holds 0.37% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG) for 245,000 shares. Prudential holds 0% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG) for 241,220 shares. Blackrock Invest Management Limited Liability last reported 435,488 shares in the company. Amer Century Companies holds 0% or 317,059 shares in its portfolio. Comerica Fincl Bank accumulated 99,669 shares or 0.01% of the stock. Jpmorgan Chase And holds 889 shares or 0% of its portfolio. Wells Fargo & Mn reported 1.03M shares or 0% of all its holdings. Millennium Mgmt Lc last reported 0.01% of its portfolio in the stock. Blackrock Institutional Na accumulated 0% or 2.62 million shares. Suntrust Banks Inc owns 16,523 shares or 0% of their US portfolio. First Advisors Lp has invested 0% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG). The Georgia-based Homrich And Berg has invested 0.01% in MiMedx Group Inc (NASDAQ:MDXG). Ubs Asset Mngmt Americas holds 47,300 shares or 0% of its portfolio. Ladenburg Thalmann Ser reported 1,737 shares or 0% of all its holdings. Manufacturers Life Ins The has 70,310 shares for 0% of their US portfolio.
Insider Transactions: Since June 16, 2016, the stock had 0 insider purchases, and 3 sales for $556,741 net activity. $219,703 worth of MiMedx Group Inc (NASDAQ:MDXG) was sold by Taylor William Charles on Thursday, July 28.
More notable recent MiMedx Group Inc (NASDAQ:MDXG) news were published by: Prnewswire.com which released: “MiMedx Announces 2015 Record Results” on February 23, 2016, also Prnewswire.com with their article: “MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo” published on July 25, 2016, Prnewswire.com published: “MiMedx Announces Nationwide Launch of AmnioFillâ„¢” on September 01, 2016. More interesting news about MiMedx Group Inc (NASDAQ:MDXG) were released by: Prnewswire.com and their article: “MiMedx Reaffirms Q3 and Full Year 2016 Guidance” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “MiMedx to Present at the 28th Annual Piper Jaffray Healthcare Conference” with publication date: November 18, 2016.
MDXG Company Profile
MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Firm operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. The Company’s biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through its donor program, a mother delivering a baby through scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. The Firm processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.